Does the FDA’s Prescribing Label Fall Short?
[ad_1] As the controversial Alzheimer’s disease (AD) drug aducanumab (Aduhelm) begins its integration into clinical practice, some physicians are concerned the drug’s prescribing label does not include adequate brain imaging recommendations to detect amyloid-related imaging abnormalities (ARIA). Specifically, the drug’s label calls for three MRI brain scans before, and during, the titration period. The problem…